Pengfei Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pengfei Gao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Wei Wang
8 shared publicationsYingwei Zhu
6 shared publicationsFuyun Zhang
5 shared publicationsYimin Mao
5 shared publicationsTongsheng Wang
4 shared publicationsBo Chen
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China
3 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Local and systemic SP-D in IPF and SARD-ILD
- 6 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessLocal and systemic SP-D in IPF and SARD-ILD
- Open Access
- 16 January 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Matrix metalloproteinases levels in induced sputum in IPF and CTD-ILD
The involvement of matrix metalloproteinases (MMPs) in the pathogenesis of interstitial lung disease (ILD) is well-supported, and circulating MMP-7 has bee
- 16 January 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessMatrix metalloproteinases levels in induced sputum in IPF and CTD-ILD
The involvement of matrix metalloproteinases (MMPs) in the pathogenesis of interstitial lung disease (ILD) is well-supported, and circulating MMP-7 has bee
- Open Access
The prognostic nutritional index improves risk stratification for acute pulmonary embolism
- Open Access
- 25 August 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Induced sputum: current progress and prospect
Induced sputum is a noninvasive, safe, cost-effective, and reproducible method that is particularly advantageous for individuals who do not naturally produce sputum or provide inadequate samples. Its higher quality than spontaneously produced sputum makes it valuable in various respiratory conditions such as chronic obstructive pulmonary disease, asthma, lung cancer, and infectious respiratory diseases. Despite its potential, the clinical use of induced sputum is limited. In conditions like interstitial lung disease, where patients often have a dry cough, induced sputum shows promise, albeit with limited research. This review emphasizes the usefulness of induced sputum in such conditions, aiming for induced sputum to be established as a routine supplementary examination in clinical settings.
- 25 August 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-9
Open AccessInduced sputum: current progress and prospect
Induced sputum is a noninvasive, safe, cost-effective, and reproducible method that is particularly advantageous for individuals who do not naturally produce sputum or provide inadequate samples. Its higher quality than spontaneously produced sputum makes it valuable in various respiratory conditions such as chronic obstructive pulmonary disease, asthma, lung cancer, and infectious respiratory diseases. Despite its potential, the clinical use of induced sputum is limited. In conditions like interstitial lung disease, where patients often have a dry cough, induced sputum shows promise, albeit with limited research. This review emphasizes the usefulness of induced sputum in such conditions, aiming for induced sputum to be established as a routine supplementary examination in clinical settings.
- 24 December 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 237, 107920
Analysis of clinical characteristics in 1940 patients with acute pulmonary embolism
- 24 December 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 237, 107920
Analysis of clinical characteristics in 1940 patients with acute pulmonary embolism
- Open Access
- 21 November 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-15
Ficolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1
Ficolins were originally identified as proteins that bind to transforming growth factor-β1 (TGF-β1). They are capable of activating the complement system through lectin pathway for immune system protection. Ficolin-2 and 3 have been identified in patients with interstitial lung diseases (ILD) and their function in these diseases is currently being explored. In contrast, the functional role of ficolin-1 in pulmonary fibrosis is still elusive and remains to be elucidated. The expression of ficolin-1 in the plasma of idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD)-ILD patients was first determined. As the orthologue of human ficolin-1, ficolin-B knockout and ficolin-B overexpression were used to establish bleomycin (BLM)-induced pulmonary fibrosis mouse model. Co-immunoprecipitation, immunofluorescence and RNA sequencing were utilized to explore and expound on the expression and the functional mechanism of ficolin-1 in pulmonary fibrosis. Compared with healthy controls, plasma ficolin-1 was significantly decreased in patients with IPF and CTD-ILD. In the bleomycin (BLM)-induced mice model, ficolin-B deficiency aggravated lung injury and fibrosis. There was also observed increase in TGF-β1 levels and enhanced downstream signaling. However, the overexpression of ficolin-B showed preventative and therapeutic efficacy against lung fibrosis. Furthermore, coimmunoprecipitation studies revealed the direct interaction between ficolin-1 and TGF-β1 in human plasma, which was further confirmed by the colocalization of ficolin-1 and TGF-β1 in lung tissues. Ficolin-1 inhibits pulmonary fibrosis by directly binding to the key profibrogenic factor TGF-β1, marking it as a potential target for therapy in the treatment of fibrotic lung diseases.
- 21 November 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-15
Open AccessFicolin-1 ameliorates pulmonary fibrosis via directly binding to TGF-β1
Ficolins were originally identified as proteins that bind to transforming growth factor-β1 (TGF-β1). They are capable of activating the complement system through lectin pathway for immune system protection. Ficolin-2 and 3 have been identified in patients with interstitial lung diseases (ILD) and their function in these diseases is currently being explored. In contrast, the functional role of ficolin-1 in pulmonary fibrosis is still elusive and remains to be elucidated. The expression of ficolin-1 in the plasma of idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD)-ILD patients was first determined. As the orthologue of human ficolin-1, ficolin-B knockout and ficolin-B overexpression were used to establish bleomycin (BLM)-induced pulmonary fibrosis mouse model. Co-immunoprecipitation, immunofluorescence and RNA sequencing were utilized to explore and expound on the expression and the functional mechanism of ficolin-1 in pulmonary fibrosis. Compared with healthy controls, plasma ficolin-1 was significantly decreased in patients with IPF and CTD-ILD. In the bleomycin (BLM)-induced mice model, ficolin-B deficiency aggravated lung injury and fibrosis. There was also observed increase in TGF-β1 levels and enhanced downstream signaling. However, the overexpression of ficolin-B showed preventative and therapeutic efficacy against lung fibrosis. Furthermore, coimmunoprecipitation studies revealed the direct interaction between ficolin-1 and TGF-β1 in human plasma, which was further confirmed by the colocalization of ficolin-1 and TGF-β1 in lung tissues. Ficolin-1 inhibits pulmonary fibrosis by directly binding to the key profibrogenic factor TGF-β1, marking it as a potential target for therapy in the treatment of fibrotic lung diseases.
- Open Access
- 17 June 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-8
Coronary stent implantation links to the occurrence of eosinophilia and interstitial pneumonia: a case report and systematic review
Background: Rapamycin has been extensively utilized for coating coronary artery stents to reduce the occurrence of restenosis, yet there has been limited research on the potential harms of rapamycin-eluting stents. Herein, We report a case of eosinophilia and interstitial pneumonia caused by a cobalt-based alloy stent eluted with rapamycin. Case presentation: The patient was admitted due to fever, cough, and expectoration symptoms. Previously, the patient had undergone a procedure of percutaneous coronary stent implantation in our hospital’s cardiology department, which led to a gradual rise in blood eosinophil count. This time, the eosinophil count was higher than the previous admission. A chest CT scan revealed multiple flocculent density increases in both lungs and bronchiectasis. The rapamycin-eluting stents may have caused eosinophilia and interstitial pneumonia, which improved after administering corticosteroids. A systematic review of relevant literature was conducted to summarize the characteristics of interstitial pneumonia caused by drug-eluting stents. Conclusion: Paclitaxel, everolimus, zotarolimus, and rapamycin are the types of drugs that can lead to drug-eluting stents, and because of the rarity of their onset, clinical doctors must be precise and prompt in diagnosing suspected cases to avoid misdiagnosis and delayed treatment.
- 17 June 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-8
Open AccessCoronary stent implantation links to the occurrence of eosinophilia and interstitial pneumonia: a case report and systematic review
Background: Rapamycin has been extensively utilized for coating coronary artery stents to reduce the occurrence of restenosis, yet there has been limited research on the potential harms of rapamycin-eluting stents. Herein, We report a case of eosinophilia and interstitial pneumonia caused by a cobalt-based alloy stent eluted with rapamycin. Case presentation: The patient was admitted due to fever, cough, and expectoration symptoms. Previously, the patient had undergone a procedure of percutaneous coronary stent implantation in our hospital’s cardiology department, which led to a gradual rise in blood eosinophil count. This time, the eosinophil count was higher than the previous admission. A chest CT scan revealed multiple flocculent density increases in both lungs and bronchiectasis. The rapamycin-eluting stents may have caused eosinophilia and interstitial pneumonia, which improved after administering corticosteroids. A systematic review of relevant literature was conducted to summarize the characteristics of interstitial pneumonia caused by drug-eluting stents. Conclusion: Paclitaxel, everolimus, zotarolimus, and rapamycin are the types of drugs that can lead to drug-eluting stents, and because of the rarity of their onset, clinical doctors must be precise and prompt in diagnosing suspected cases to avoid misdiagnosis and delayed treatment.
- Open Access
- 23 January 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-9
Diagnostic accuracy of thoracic CT to differentiate transudative from exudative pleural effusion prior to thoracentesis
Background: Computed tomography (CT) scan is commonly performed for pleural effusion diagnostis in the clinic. However, there are limited data assessing the accuracy of thoracic CT for the separation of transudative from exudative effusions. The study aimed to determine the diagnostic value of thoracic CT in distinguishing transudates from exudates in patients with pleural effusion. Methods: This is a two-center retrospective analysis of patients with pleural effusion, a total of 209 patients were included from The First Affiliated Hospital of Henan University of Science and Technology as the derivation cohort (Luoyang cohort), and 195 patients from the First Affiliated Hospital of Zhengzhou University as the validation cohort (Zhengzhou cohort). Patients who underwent thoracic CT scan followed by diagnostic thoracentesis were enrolled. The optimal cut-points of CT value in pleural fluid (PF) and PF to blood CT value ratio for predicting a transudative vs. exudative pleural effusions were determined in the derivation cohort and further verified in the validation cohort. Results: In the Derivation (Luoyang) cohort, patients with exudates had significantly higher CT value [13.01 (10.01–16.11) vs. 4.89 (2.31–9.83) HU] and PF to blood CT value ratio [0.37 (0.27–0.53) vs. 0.16 (0.07–0.26)] than those with transudates. With a cut-off value of 10.81 HU, the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CT value were 0.85, 88.89%, 68.90%, 43.96%, and 95.76%, respectively. The optimum cut-value for PF to blood CT value ratio was 0.27 with AUC of 0.86, yielding a sensitivity of 61.11%, specificity of 86.36%, PPV of 78.57%, and NPV of 73.08%. These were further verified in the Validation (Zhengzhou) cohort. Conclusions: CT value and PF to blood CT value ratio showed good differential abilities in predicting transudates from exudates, which may help to avoid unnecessary thoracentesis.
- 23 January 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-9
Open AccessDiagnostic accuracy of thoracic CT to differentiate transudative from exudative pleural effusion prior to thoracentesis
Background: Computed tomography (CT) scan is commonly performed for pleural effusion diagnostis in the clinic. However, there are limited data assessing the accuracy of thoracic CT for the separation of transudative from exudative effusions. The study aimed to determine the diagnostic value of thoracic CT in distinguishing transudates from exudates in patients with pleural effusion. Methods: This is a two-center retrospective analysis of patients with pleural effusion, a total of 209 patients were included from The First Affiliated Hospital of Henan University of Science and Technology as the derivation cohort (Luoyang cohort), and 195 patients from the First Affiliated Hospital of Zhengzhou University as the validation cohort (Zhengzhou cohort). Patients who underwent thoracic CT scan followed by diagnostic thoracentesis were enrolled. The optimal cut-points of CT value in pleural fluid (PF) and PF to blood CT value ratio for predicting a transudative vs. exudative pleural effusions were determined in the derivation cohort and further verified in the validation cohort. Results: In the Derivation (Luoyang) cohort, patients with exudates had significantly higher CT value [13.01 (10.01–16.11) vs. 4.89 (2.31–9.83) HU] and PF to blood CT value ratio [0.37 (0.27–0.53) vs. 0.16 (0.07–0.26)] than those with transudates. With a cut-off value of 10.81 HU, the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CT value were 0.85, 88.89%, 68.90%, 43.96%, and 95.76%, respectively. The optimum cut-value for PF to blood CT value ratio was 0.27 with AUC of 0.86, yielding a sensitivity of 61.11%, specificity of 86.36%, PPV of 78.57%, and NPV of 73.08%. These were further verified in the Validation (Zhengzhou) cohort. Conclusions: CT value and PF to blood CT value ratio showed good differential abilities in predicting transudates from exudates, which may help to avoid unnecessary thoracentesis.
- Open Access
- 24 November 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-8
Increased expression of ficolin-1 is associated with airway obstruction in asthma
Background: The activated complement cascade is involved in asthmatic airway inflammation. Ficolins are essential for innate immunity and can activate the complement lectin pathway. Despite this, the significance of ficolins in asthma has yet to be determined. This study aimed to explore the presence of ficolins in individuals with asthma and to determine the relationship between ficolins and clinical characteristics. Methods: For the study, 68 asthmatic patients and 30 healthy control subjects were recruited. Enzyme-linked immunosorbent assay was used to determine plasma ficolin-1, ficolin-2, and ficolin-3 concentrations both before and after inhaled corticosteroid (ICS) therapy. Further, the associations of plasma ficolin-1 level with pulmonary function and asthma control questionnaire (ACQ) score were examined in the asthma patients. Results: Patients with asthma exhibited significantly elevated plasma ficolin-1 levels (median, 493.9 ng/mL; IQR, 330.2–717.8 ng/mL) in comparison to healthy controls (median, 330.6 ng/mL; IQR, 233.8–371.1 ng/mL). After ICS treatment, plasma ficolin-1 (median, 518.1 ng/mL; IQR, 330.2–727.0 ng/mL) in asthmatic patients was significantly reduced (median, 374.7 ng/mL; IQR, 254.8–562.5 ng/mL). Additionally, ficolin-1 expressions in plasma were significantly correlated with pulmonary function parameters and ACQ score in asthmatic patients. Asthma patients with higher plasma ficolin-1 levels demonstrated poorer lung function than those with lower plasma ficolin-1 levels. Conclusions: The results revealed that asthmatic patients had higher plasma ficolin-1 concentrations, which decreased after ICS treatment and were linked to their lung function, implying a potential involvement of ficolin-1 in asthma pathogenesis.
- 24 November 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-8
Open AccessIncreased expression of ficolin-1 is associated with airway obstruction in asthma
Background: The activated complement cascade is involved in asthmatic airway inflammation. Ficolins are essential for innate immunity and can activate the complement lectin pathway. Despite this, the significance of ficolins in asthma has yet to be determined. This study aimed to explore the presence of ficolins in individuals with asthma and to determine the relationship between ficolins and clinical characteristics. Methods: For the study, 68 asthmatic patients and 30 healthy control subjects were recruited. Enzyme-linked immunosorbent assay was used to determine plasma ficolin-1, ficolin-2, and ficolin-3 concentrations both before and after inhaled corticosteroid (ICS) therapy. Further, the associations of plasma ficolin-1 level with pulmonary function and asthma control questionnaire (ACQ) score were examined in the asthma patients. Results: Patients with asthma exhibited significantly elevated plasma ficolin-1 levels (median, 493.9 ng/mL; IQR, 330.2–717.8 ng/mL) in comparison to healthy controls (median, 330.6 ng/mL; IQR, 233.8–371.1 ng/mL). After ICS treatment, plasma ficolin-1 (median, 518.1 ng/mL; IQR, 330.2–727.0 ng/mL) in asthmatic patients was significantly reduced (median, 374.7 ng/mL; IQR, 254.8–562.5 ng/mL). Additionally, ficolin-1 expressions in plasma were significantly correlated with pulmonary function parameters and ACQ score in asthmatic patients. Asthma patients with higher plasma ficolin-1 levels demonstrated poorer lung function than those with lower plasma ficolin-1 levels. Conclusions: The results revealed that asthmatic patients had higher plasma ficolin-1 concentrations, which decreased after ICS treatment and were linked to their lung function, implying a potential involvement of ficolin-1 in asthma pathogenesis.
- 1 April 2019
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 49 (4) , 552
PTX3 and D-dimer in children with asthma: A real-world study-Reply
- 1 April 2019
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 49 (4) , 552
PTX3 and D-dimer in children with asthma: A real-world study-Reply